Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2
Limitation of Acinetobacter baumannii treatment by plasmid-mediated carbapenemase ARI-2
复制标题
DOI:
10.1016/s0140-6736(05)78210-6
复制
发表时间:
1998-01-17
期刊:
影响因子:
168.9
通讯作者:
Amyes, SGB
中科院分区:
文献类型:
--
作者:
Brown, S;Bantar, C;Amyes, SGB
Acinetobacter species now account for 10% of nosocomial infections in intensive therapy units (ITU) in Europe. They are invariably multiresistant, and one major concern is the increasing incidence of carbapenem-resistant isolates, since these antibiotics are frequently the therapeutic choice for these infections. Carbapenem resistance in South America has already reached levels that significantly influence therapeutic choices (Carlos Bantar, unpublished data), and this looks set to be a problem in some European countries. 1 ARI-1, a plasmid-mediated enzyme capable of hydrolysing imipenem, was the first carbapenemase to be isolated from this genus. 2 We report a novel plasmid-mediated carbapenemase (ARI-2) from a multiresistant clinical isolate of A baumannii from Argentina (first described in 1996). 3The strain (1622) was isolated from a bronchial alveolar lavage specimen and identification was carried out by the API 20NE identification system. Minimum inhibitory concentrations (MIC) of a range of antibiotics were determined by the agar dilution method. 4 A cell-free extract of strain 1622 was prepared and-lactamase bands were detected by isoelectric focusing (IEF) on a polyacrylamide gel. Inhibitors were applied to the gel to detect enzyme inhibition. Imipenem hydrolysis was demonstrated by a microbiological assay. 2 This assay was modified to increase sensitivity and quantify the activity of the enzyme. 3 Curing